for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Business

Valeant needs to find stability, more transparency-Jeff Loo

Posted

S&P Investment Advisory Services Jeffrey Loo talks about why he has a "buy" rating on controversial drug company Valeant, which just added three new members to its board. Bobbi Rebell reports.

Business

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up